Pharmacokinetics and Pharmacodynamics of subcutaneous applied insulin aspart administered with the FlexPen insulin pen compared to inhaled insulin administered with the Exubera device.

Trial Profile

Pharmacokinetics and Pharmacodynamics of subcutaneous applied insulin aspart administered with the FlexPen insulin pen compared to inhaled insulin administered with the Exubera device.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin; Insulin detemir
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 25 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top